Management of muscular dystrophy during osteoarthritis disorder: A topical phytotherapeutic treatment protocol by Ganguly, Apurb
Caspian J Intern Med 2019; 10(2):183-196  
DOI: 10.22088/cjim.10.2.183 
    Original Article 
 
 
 
 
 
 
Apurba Ganguly (PhD) 1* 
 
 
 
1. Department of Research and 
Development, OPTM Research 
Institute, India 
 
 
  
* Correspondence: 
Apurba Ganguly, OPTM Research 
Institute, 145 Rashbehari Avenue, 
Kolkata - 700029, India 
 
 
E-mail: 
apurbaganguly15@gmail.com ‏ 
Tel: 00919830389616  
Fax: 00919830389616  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Received: 11 Jun 2018  
Revised: 16 Aug 2018 
Accepted: 28 Aug 2018 
 
Management of muscular dystrophy during osteoarthritis 
disorder: A topical phytotherapeutic treatment protocol 
 
Abstract 
Background: Creatine kinase-muscle (CK-MM) and aldolase A (AldoA) levels are proven 
to be realistic biochemical markers to detect muscular dystrophy during osteoarthritic 
disorders (MD-OADs). The aim of this study is to normalize the MD-OADs characterized 
by muscle weakness, atrophy, inflammatory disorders, pain with chronic arthropathy by 
specialized topical phytotherapeutic treatment. 
Methods: Baseline data were collected and evaluated from 153 patients, aged 
59.89±11.37years, and suffering with MD-OADs for 7.89±1.90 years. Serum CK-MM and 
aldoA levels were measured at baseline and after a six- week treatment using the 
appropriate kits. All patients underwent standardized physical, radiographic examinations 
and completed a questionnaire. All the patients were treated with topical application of 
phytoconstituents from the extracts of seven Indian medicinal plants namely Cissus 
quadrangularis, Calotropis gigantea, Zingiber officinalis, Rosemarinus officinale, 
Boswellia serratia, Curcuma longa and Withata somnifera mixed with sesame oil and 
beehives wax for six-week. 
Results: The elevated levels of biomarkers, CK-MM and aldoA, were reduced to their 
mean±SEM values 82.77±1.32 and 4.94±1.30U/L, respectively at the end of six-week 
treatment and the improvements of deranged anatomical features, Pearson’s correlation 
coefficients, international-approved pain related abnormalities (VAS, WOMAC, KPS and 
KOOS) and reduction of weight at the end of treatment were all highly significant 
(p<0.0001). 
Conclusion: It is firmly confirmed that MD-OADs resulted with the elevated levels of 
CK-MM, and AldoA, along with deranged anatomical features (KGB, DTM, DCM, DAP, 
DBP, SLR, KFS and KES) and pain related parameters (VAS, WOMAC-index, KPS, 
KOOS and BMI) can be successfully normalized by topical phytotherapeutic treatment 
protocol. 
Keywords: Muscular dystrophy; Specific biomarkers; Phytotherapy; Normalized serum 
markers; OAD with muscular dystrophy. 
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According to Newman (1), muscular dystrophy (MD) is a group of disorders in 
which progressive loss of muscle mass due to interference with the production of muscle 
protein called dystrophin, (first identified in 1987 by Louis M. Kunket), essential for 
building and repairing muscles, lead to muscular wasting, muscle weakness and 
degeneration, whereas osteoarthritic disorders (OADs) are commonly characterized by the 
potential loss of joint cartilage as well as osteophyte formation, connective tissue damage, 
pain symptoms, joint effusion, restricted movement of joints, tenderness and crepitus in the 
joints (2-6). But several muscle degenerations are leading to muscular dystrophy also 
matter of great concern during the progression of OADs. 
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Researches have been well-documented with regard to 
the impairment of different muscles during MD-OADs (7-
10) and also it was reported that women are more vulnerable 
than men (7, 9, 11). 
There are several types of MD such as Duchenne 
muscular dystrophy (DMD) and Becker muscular dystrophy 
(BMD) which are very common. But none of DMD or BMD 
is involved in MD-OAD as it does not occur relating to their 
phenomenon (12). The normal symptoms of MD-OAD 
include: a waddling gait; pain and stiffness in the muscles; 
difficulty with running and jumping; difficulty in sitting and 
standing; frequent falls; shortening of muscles and tendons 
which lead to further limiting movement of joints, cartilage 
damage effusion, bone hypertrophy and lordosis (13).  Both 
DMD and BMD are associated with a heart condition called 
cardiomyopathy which includes an irregular heartbeat, 
shortness of breath, fatigueless etc. developed in childhood 
or in adolescence but the above phenomena are not indicated 
in MD-OAD. Interestingly, it is to be noted that these two 
characteristics during DMD and BMD differed in their 
severity, age of onset, and rate of progression, as in DMD, 
muscle weakness tends to appear in early childhood while 
BMD occurs later in childhood or in adolescence with 
slower rate of progression, but MD-OAD occurs >50 years 
of age with muscle atrophy and weakness along with chronic 
arthropathy. Moreover, OADs are closely related to 
sarcopenia in which reduction of muscle mass was observed 
followed by failure of muscle strength and functional ability 
(14-16). Generally, estimation of serum aldolase level helps 
to diagnose MDs, neuromuscular disorders, and wasting of 
skeletal muscle (17-20). From past study by Sibley and 
Lehninger (21), it was reported that hyperaldolasaemia leads 
to MD. Previously, MD was identified by knowing elevated 
level of aldolase in serum, but researchers have found that 
the estimation of both muscle creatine kinase as well as 
aldolase levels in combinations can be suitable biochemical 
markers to detect MD along with skeletal muscle damage 
(22). From decade, the estimation of creatine kinase-muscle 
(CK-MM), which is found to be elevated and can be 
estimated through CPK-MM isoforms (23-28). In this 
context, several researchers have suggested muscular 
damage along with osteoarthritis that can be treated through 
sports and exercise for the therapy of muscular weakness, 
functional disability, etc. (29-31). Till date no medication 
was reported to prevent or reverse MD-OADs except pain 
relief and prevent inflammation by non-steroidal anti-
inflammatory drugs (NSAIDs) or steroid drugs (32). But 
their use is associated with increased gastrointestinal and 
cardiovascular risk (33). But no specific treatment is 
available for MD-OADs which can reduce the biochemical 
parameters such as CK-MM and aldoA representing muscle 
degeneration, bone erosion and skeletal muscles damage.  
Moreover, the author has already developed a unique 
deranged anatomical measuring protocol to identify quantum 
of damage of muscles and tissues and also other biomarkers 
such as calcium, phosphorus, ratio of calcium and 
phosphorus and level of parathyroid hormone to identify the 
condition of damage bone during MD in OAD patients (28, 
34-35).  Recently the author has established the diagnostic 
protocol for MD-OADs evidenced by biochemical and 
anatomical parameters (36). It has been attempted earlier that 
increased CK-MM and AldoA levels in blood decreased 
after completion of topical application of natural compounds 
(phytochemicals) extracted from seven medicinal plants such 
as Calotropis gygantea (root and leaves), Cisssus 
quadrangularis (whole plant), Zingiber officinale (rhizome), 
Rosmarinus officinalis (leaves and flowers), Boswellia 
serrata (resin), Curcuma longa (rhizome) and Withania 
somnifera (root) (37-39). According to Ganguly A (37-38), 
this is a novel technique and for the first time it was 
observed with the help of aqueous phytoextraction as 
remedial measures.  
The present study was attempted for normalization of 
MD-OADs by analyzing the decreasing serum levels of CK-
MM and aldoA in the patients before and after the treatment 
using phytoconstiuents extracted from the abovementioned 
seven plants mixed with sesame oil and beehive wax by 
specialized treatment protocol which have not been studied 
yet.  
 
 
Methods   
Recruitment of patients: From nine center of OPTM Health 
Care (P) Ltd 315 Indian patients (222 females and 93 males), 
aged 40 to 70 years old were selected for the study from July 
2017 to December 2017, based on the sign and symptoms as 
described in earlier studies (27). The total number of 153 
patients suffering for more than five years with MD-OADs 
was selected using exclusion criteria summarized in (table 
1). The study protocol was evaluated and approved by the 
OPTM Research Institute Ethics Committee. An Institutional 
Review Board-approved consent form for the physical 
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examinations, blood sample collections and other 
radiological examinations required for the study was signed 
by all the patients in the first phase of the screening 
procedure. 
Table 1. Exclusion criteria during selection of patients 
Out of 315 patients, 162 patients (114 females and 48 males) were excluded. 
After check-up 
A. 112 patients (86 females and 26 males) were excluded for the following reasons with: 
 
1. cuts, wounds or any type of chronic skin disease (12 females and 4 males).  
2. parallel multiple drug dependence such as NSAIDS, corticosteroids etc.  (14 females and 4 males). 
3. surgical implants (8 females and 3 males).  
4. a pacemaker (9 females and 2 males). 
5. a history of cancer, including caranomatosis and granulocytic leukemia (11females and  3 males). 
6. a history of severe neurological diseases (12 females and 2 males) 
7. a history of chronic liver, kidney and heart diseases ( 12 females and 4 males) and 
8. patients who did not agree to a physical evaluation  (8 females and 4 males) 
B.    34 patients (17 females and 17 males) were also additionally excluded for having another pathological 
condition that could explain the existing symptoms such as: 
 
1. rheumatic diseases,  
2. osteochondritis diseases,  
3. inter-articular fractures,  
4. congenital dysplasia,  
5. radicular syndrome,  
6. joint symptoms caused by malignant tumors,  
7. Baker’s cyst,  
8. Perthes disease,  
9. Plica syndrome,  
10. dermatomyositis and polymyositis diseases,  
11. iliopectineal or trochanteric bursitis,  
12. ischemic bone necrosis  
13. ligament or meniscus damage. 
Discontinued (dropped out) during treatment 
C. 16 patients (11 females and 5 males) discontinued their treatment in the clinic because of :  problems of 
transportation; shortage of helping hands at old age;  unable to apply medicines at home, twice/thrice a day 
and transferring the jobs in other city as under: 
 
a) 7 patients after a week (3 females and a male) 
b) 7 patients after the second week (4 females and 2 males)  
c) 6 patients after the third week (2 females and a male)  
d) 5 patients after the mid of fourth week (2 females and a male) 
 
Study design: After the analysis of exclusion criteria, each 
patient of 153 completed a questionnaire, providing details 
regarding demographics, medical history, nutritional status, 
ethnic barriers and work status at the baseline and 
summarized in table 2.  
 
Evaluation of anatomical features: Physical examinations 
were evaluated at the baseline and at the end of 6 weeks of 
post treatment including anatomical measurements as per 
established protocol of Ganguly (27) and range of motions 
(ROMs) was used in accordance with the American 
Academy of Orthopedic Surgeons (AAOS) (40). 
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Table 2. Demographic data and baseline characteristics of the study subjects 
Characteristic Combined Female Male 
No of subjects (%) 153 108 (70.59) 45 (29.41) 
Mean age (SD) in years 59.89 ( 11.37) 59.38 (10.21) 61.12 (13.68) 
Mean weight (SD) in kg 69.71 (5.05) 69.12 (5.11) 71.13 (6.12) 
Mean height (SD) in meter 1.58 (0.92) 1.55 (0.88) 1.67 (0.93) 
Mean BMI (SD) in kg/m² 27.86 (6.94) 28.80 (6.64) 25.59 (7.11) 
Mean symptom duration in years (SD) 7.89 (1.90) 7.78(1.78) 8.12 (2.11) 
Indian ethnic group (%) 
Bengali 65(42.48 )  54 (50.00 ) 11 (24.44 ) 
Gujrati 12 (7.84 ) 7 (6.48 ) 5 (11.11 ) 
Marwaree 14 (9.15 ) 7 (6.48 ) 7(15.55 ) 
Marathi 13 (8.51 ) 8 (7.41 ) 5 (11.11 ) 
Tamil 15 (9.80 ) 11 (10.18 ) 4 (8.89 ) 
Punjabi 13( 8.51) 7(6.48 ) 6 (13.33 ) 
Shindhi 11 (7.18 ) 8 (7.41 ) 3 (6.68 ) 
North East India 10 (6.53 ) 6 (5.56 ) 4 (8.89 ) 
Dietary habits (%)    
Vegetarian 97 (63.40 ) 71 (65.74 ) 26 (57.78 ) 
Non- vegetarian 56 (36.60 ) 37 (34.26 ) 19 (42.22 ) 
Other habits 
Smoking 45 (29.41)        22 (20.37 )  23 (51.11 ) 
Drinking alcohol 
14(9.15)  
 
6 ( 5.55) 
 
8 (17.78 ) 
Drinking tea and coffee 69 (45.10 ) 57 (52.78 ) 12 (26.67 ) 
Chewing tobacco 25 (16.34 ) 23 (21.30 ) 2 (4.44 ) 
Analysis of radiological reports (%) 
 KOA in right knee with osteophytes 51 (33.33 ) 35 ( 32.41 ) 16( 35.56 ) 
 KOA in left knee with osteophytes 57 (37.25 ) 39 (36.11 ) 18 (40.00 ) 
Degenerative changes in lumber region 45 (29.42 ) 34 (31.48 ) 11 (24.44 ) 
Work status (%) 
Employed fulltime 34 (22.22 ) 12 (11.11 ) 22 (48.89 ) 
Employed part time 7 (4.57 ) 4 (3.70 ) 3 (6.67 ) 
Housewife / Home- maker 66 (43.15 ) 66 (61.11 ) - 
Retired 18 (11.76 ) 10 (9.26 ) 8 (17.78 ) 
Self employed 28 (18.30 ) 16 (14.82 ) 12 (26.66 ) 
Marital status (%) 
Single 8 ( 5.23) 3 ( 2.78) 5 (11.11 ) 
Married 111 (72.55 ) 86 (79.63 ) 25 (55.55 ) 
Separated 8 (5.23 ) 3 (2.78 ) 5 (11.11) 
Divorced 11 (7.19 ) 5 (4.63 ) 6 (13.34 ) 
Widowed 15 (9.80 ) 11 (10.18 ) 4 (8.89 ) 
Multiple complaints or comorbidities (%) 
Constipation 147 (96.08 ) 105 (97.22 ) 42 (93.33 ) 
Acidity and reflux 148 (96.73 ) 104 (96.30 ) 44 (97.78 ) 
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Insomnia 112 (73.20 ) 80 (74.07 ) 32 (71.11 ) 
Varicose veins 81 (52.94 ) 59 (54.63 ) 22 (48.89 ) 
Urinary incontinence 89 (58.17 ) 60 (55.55 ) 29 (64.44 ) 
Crepitus during knee flexion 111 (72.55 ) 96 (88.89 ) 15 (33.33 ) 
Morning stiffness (<30 min.) 119 (77.78 ) 102 (94.44 ) 17 (37.78 ) 
Measures taken to diminish pain and inflammation (%) 
Knee cap uses 88 (57.52 ) 51 (47.22 ) 37 (82.22 ) 
Lumbar belt uses 25(16.34 ) 15 (13.89 ) 10 (22.22 ) 
Paracetamol and NSAID use 142 (92.81 ) 99 (91.67 ) 43 (95.56 ) 
Arthrocentesis (four months ago) 11 (7.19 ) 3 (2.78 ) 8 (17.78 ) 
Use of hyaluronic acid injection 25 (16.34 ) 14 (12.96 ) 11 (24.44 ) 
Use of corticosteroid injection 37 (24.18 ) 25 (23.15 ) 12 (26.67 ) 
Massage with herbal or other gels 144 (94.12 ) 103 (95.37 ) 41 (91.11 ) 
Homeopathic treatment 149 (97.38 ) 107 (99.07 ) 42 (93.33 ) 
Ayurvedic treatment 148 (96.73 ) 104 (96.30 ) 44 (97.78 ) 
Stick/walker use 25 (16.34 ) 15 (13.89 ) 10 (22.22 ) 
Supplements taken to reduce pain or improve fitness (%) 
Calcium 107 (69.93 ) 81 (75.00 ) 26 ( 57.78) 
Vitamin D 115(.75.16 ) 77 (71.30 ) 38 ( 84.44) 
Glucosamine 89 (58.17 ) 71(65.74 ) 18 (40.00 ) 
Glucosamine and chondroitin 51 (33.33 ) 29 (26.85 ) 22 (48.89 ) 
 
 
Evaluation of biochemical parameters: A 5-ml blood 
sample was collected in a plain vial from each patient with 
MD-OAD before and after the treatment. Blood samples 
were then centrifuged at 1000×g for 10 min at 4
o 
C to obtain 
serum. Finally, the serum was used to analyze CK-MM, and 
aldoA levels for   each patient. The biomarkers were 
rigorously analyzed. CK-MM (U/L) levels were 
quantitatively assessed using a Creatine Kinase- MM kit 
(CK-MM/CPK-MM/CK-3) and an immunoassay (Aalto 
Scientific, Limited, USA). The kit was developed based on 
the methods reported by Walker (41). AldoA levels (U/L) 
were quantified using an ALDOLASE (ALS) RX MONZA 
AD 189 kit (Randox Laboratories Ltd, Antrim, UK) based 
on a photometric assay at a wavelength of 340 nm. The kit 
was developed according to the method reported by 
Thompson and Vignos (42). The subjects suffering from 
MD-OADs with muscle degeneration and skeletal muscle 
damage were studied to identify a specific biochemical 
parameter, such as CK-MM, and aldoA levels, in the 
affected population 
The standard error of the mean (SEM) and their mean 
differences (MDs), 95% confidence intervals (CIs), and p-
values of the two biomarkers such as CK-MM and aldoA  
 
 
and their ratios were evaluated at the baseline and at the end 
of the six-week treatment. Their percentages of 
mprovements after the treatment were graphically evaluated. 
Evaluation of pain under Visual analogue scale (VAS): 
Visual analogue scale (VAS) for pain is a one-dimensional 
measure of pain intensity (43).  The pain intensity in the last 
24 hours was evaluated for each patient at the baseline and at 
the end of treatment. The percentage of improvements was 
evaluated at the end of treatment for all the patients 
separately. Their mean, SD and p-values for overall and 
separately by gender were also graphically evaluated  
Evaluation of pain, stiffness and physical function under 
WOMAC Index: The scoring data for pain, stiffness and 
functional disability of individual patient were evaluated 
using ‘The Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC index) as per method 
followed by previous researchers (44). The percentage of 
improvements of pain, stiffness and physical functional 
abilities were evaluated at the end of treatment for all the 
patients separately. Their mean, SD and p-values overall and 
separately by gender were graphically evaluated. 
Evaluation of Karnofsky Performance Status (KPS) 
score: Karnofsky performance status (KPS) score is used to 
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determine a patient’s prognosis to carry out daily activities. 
A higher score indicates the patient is better able to carry out 
daily activities and its range from 0 to 100 (45). The 
percentage of improvements was evaluated at the baseline 
and at the end of the treatment for all the patients separately. 
Their mean, SD and p-values overall and separately by 
gender were graphically evaluated. 
Evaluation of Knee-injury Osteoarthritis Outcomes Scale 
(KOOS): The Knee-injury Osteoarthritis Outcomes Scale 
(KOOS) developed by Ewa Roos and co-authors in the 
1990s (46) was used to assess the patient’s opinion about 
their knee and associated problems as an instrument. All the 
scoring data under KOOS were evaluated for each patient at 
the baseline and at the end of the six-week treatment. Their 
mean, SD and p-values overall and separately by gender 
were also graphically evaluated. 
Evaluation of body mass index (BMI): Body weight in 
kilogram was measured without shoes or heavy clothing 
using an electronic scale. Height in meter was measured 
without shoes using a wall-mounted stadiometer (47). Body 
mass index (BMI, kg/m
2
) was calculated for all the patients 
based on measured weights and heights at pre- and post-
treatment. The percentage of improvements was evaluated at 
the end of treatment for all the patients separately. Their 
mean, SD and p-values overall and separately by gender 
were also graphically evaluated. 
Evaluation of Pearson’s correlation coefficients between 
two biomarkers: The Pearson’s correlation coefficients 
between two biochemical markers such as CK-MM at the 
baseline (CK-MM
b
) and CK-MM after the treatment (CK-
MM
t
), aldoA at the baseline (Aldo A
b 
) and aldoA after the 
treatment (aldoA
t 
),  the ratio of (CK-MM
b
 : aldoA
b
)  and 
(CK-MM
t
 : aldoA
t 
) along with their respective p-values 
were evaluated.. 
Evaluation of radiological images with the Kellgren and 
Lawrance system: Radiological images for both knee joints 
and lumbo-sacral spine of 153 combined-sex patients, were 
collected, both anterior-posterior (AP) and lateral views, at 
pre- and post-treatment evaluations. The AP views of the 
knee joints of 153 patients are assessed by K-L grading scale 
(48). The AP view of knee joints and lumbar vertebrae x-ray 
images of two such patients, (before and after the treatment) 
are separately evaluated.  
Evaluation of Indian medicinal plants, their 
phytoconstituants from aqueous extracts and their 
established mechanisms of action: The treatment involves 
topical application of phytoconstituents from the extracts of 
seven Indian medicinal plants namely Cissus quadrangularis 
(whole plant), Calotropis gigantea (root and leaves), 
Zingiber officinale (rhizome), Rosemarinus officinalis 
(leaves and flowers), Boswellia serrata (resin), Curcuma 
longa  (rhizome) and Withania somnifera (root) mixed with 
virgin sesame oil (extracted from seeds at room temperature) 
and  beeswax to make viscous phyto-based oil without using 
any preservatives or chemicals to preserve the phytochemical 
properties of plants intact (36-39).  
Phytotherapeutic treatment protocol: The treatment 
protocol is based on well-defined certain principles and 
theories and also based on the applications of well-known 
chemical, mechanical, thermal and electrical stimuli which 
improve the fundamental properties of all muscles such as 
excitability, conductivity, contractibility, elasticity and 
viscosity (27-28, 36-37). Each 30 ml of said viscous phyto-
based oil prepared from the extracts of seven Indian  
medicinal plants mixed with virgin sesame oil and beehive-
wax is to be applied with the tip of three fingers in particular 
technique over the skin three times a day with minimum 
interval of two hours for six weeks ; lying in six different 
postural positions such as supine, prone, right and left 
contra-lateral and right and left cross contra-lateral in 
different programmed sequences to nourish the affected 
group of badly damaged muscles and nerves in the legs and 
lumber regions during  the disease. Therefore, the present 
treatment protocol has been followed the earlier studies (27, 
28, 36-37, 49-55). 
External study reviewers: All results and data before and 
after the treatment were evaluated by an external reviewing 
panel, not in contract with the registry patients.  
Data collection and Statistical analysis: Data were 
summarized using descriptive statistics for continuous 
variables (e.g., mean,  standard deviation, standard error of 
the mean, number of patients, minimum, maximum), 
frequency tables, or ratios for discrete variables, and 95% 
confidence intervals. Statistical analyses were done using 
software (Graph Pad Prism, Version5.0) with repeated 
measures for student-t test to determine the significant values 
at p<0.05 level along with r (Pearson’s correlation 
coefficient) values to determine strong and weak correlation 
among two variables for measuring different improvement 
parameters of combined-sex, female and male patients 
separately. An alpha level of 5% was established i.e., a p-
value less than 0.05 was considered statistically significant. 
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Results 
Enrolment and baseline characteristics of patients: A 
total of 153 patients aged 59.89±11.37 years (71% women) 
were included in the study. All the patients were suffering 
from MD-OAD for 7.89±1.90 years having massive muscle 
wasting specially in the thigh and calf regions, bone erosion and 
skeletal muscle damaged confirmed by the serum tests of CK-MM 
and aldoA and radiological images. The baseline demographic 
characteristics of all patients are shown in table 2.  
 
Biochemical parameters: Table 3 shows that the mean 
levels of CK-MM and  Aldo were  reduced  to  their normal 
limits ( CK-MM: for male <171 and female <145 U/L and 
aldoA: <7.6U/L and their differences and the ratios of CK-
MM and aldoA at the baseline (CK-MM
b
: aldoA
b
)   and at 
the end of six-week treatment (CK-MM
t
: aldoA
t
) were 
highly significant (p<0.0001) when compared to the baseline 
for both overall and separately by gender. 
 
Table 3. Statistical analysis of CK-MM, aldoA and ratio of CK-MM and aldoA of 153 patients 
 
Biochemical 
 parameter 
Gender 
Baseline End of 6-week 
Improvements on elevated levels of biomarkers 
 at the end of 6-week 
MD 
95% CI of difference 
 P-value 
Mean (SEM) Mean (SEM) Lower limit Upper limit 
CK-MM  
(U/L) 
Female (n=108) 206.45 (8.207) 77.99 (1.230) 128.46 112.10 144.82 <0.0001 
Male (n=45) 252.97 (15.408) 94.24 (2.697) 158.73 127.64 189.81 <0.0001 
Aldo A U/L) 
Female (n=108) 7.25 (0.264) 4.91 (1.230) 2.34 1.77 2.91 <0.0001 
Male (n=45) 6.70 (0.276) 5.02 (0.201) 1.68 1.00 2.36 <0.0001 
Ratio of  
CK-MM & 
AldoA 
Female (n=108) 30.50 (1.172) 17.05 (0.542) 13.45 10.90 15.99 <0.0001 
Male (n=45) 
40.42 (2.785) 20.76 (1.425) 19.66 13.44 25.88 
<0.0001 
 
Table 4 shows the levels of correlation coefficients 
between CK-MM at the baseline (CK-MM
b
) and at the end 
of treatment (CK-MM
t
), were not significant (P=0.024, 
P=0.574 and P=0.434, respectively) for combined-sex 
patients, female-only and male-only patients.  
The correlation coefficients between aldoA at the 
baseline (aldoA
b
) and at the end of treatment (Aldo A
t
) and 
the ratio of CK-MM and Aldo A at the baseline (CK-MM
b
 : 
AldoA
b
) and at the end of 6-week of treatment (CK-MM
t
 : 
aldoA
t 
) were all highly significant (P=0.000) both overall 
and separately by gender.  
The correlation coefficients between CK-MM at baseline 
(CK-MM
b
) and aldoA at the baseline (aldoA
b
) were all 
highly significant (p<0.05).  
The correlation coefficients between CK-MM at baseline 
(CK-MM
b
) and aldoA at end of treatment (aldoA
t
) were not  
 
significant (P=0.353, P=0.228 and P=0.828, respectively) for 
combined-sex patients, female-only patients and male-only 
patients.  
The percentage of improvements of CK-MM and aldoA 
after the end of treatment were highly significant 
(p<0.0001) both overall and separately by gender and shown 
in figure 1. 
Pain, stiffness, performance parameters and BMI: The 
percentage of improvements: on pain under VAS; on pain, 
stiffness and physical functions under WOMAC index; on 
performance on daily activities under KPS; of the five 
separately scored subscales under KOOS knee survey and 
reduction of body weight confirmed by BMI after the 
treatment for combined-sex, female-only and male-only 
patients were all highly significant (p<0.05) both overall and 
separately by gender depicted in figures 2-6. 
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Table 4. Analysis of correlation coefficients of biomarkers between baseline and end of 6-week treatment 
Gender 
CK-MM
b
 vs.  
CK-MM
t
 
Aldo A
b 
 vs.  
Aldo A
t
 
CK-MM
b
  vs.  
Aldo A
b
 
CK-MM
t 
 vs.   
Aldo A
t
 
CK-MM
b
: Aldo A
b 
 vs. 
CK-MM
t
: Aldo A
t
 
R-value P-value R-value P-value R-value P-value R-value P-value R-value P-value 
Female-only 
(n=108) 
0.055 0.574 0.638 0.000 0.286 0.002 0.117 0.228 0.438 0.000 
Male-only 
(n=45) 
-0.120 0.434 0.679 0.000 0.105 0.494 -0.033 0.828 0.444 0.000 
CK-MMb: baseline data of CK-MM,   CK-MMt: data after treatment of CK-MM,  Aldo Ab: baseline data of aldoA, aldoAt: data after treatment of aldoA 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Percentage of improvement of biomarkers CK-MM and aldoA and their ratios at the end of the 6-week treatment 
(*p<0.0001) 
 
 
 
 
 
 
 
 
 
 
Figure 2: percentage of Improvement of pain under VAS after 6-week treatment (*p<0.0001) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: % of Improvement of pain, stiffness & physical function under WOMAC index after the 6-week treatment 
(*p<0.0001) 
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Figure 4: % of Improvement of pain under KPS after 6-week treatment (*p<0.0001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: % of Improvement on reduction of body weight as assessed by BMI after 6-week treatment (*p<0.0001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: KOOS Profiles before and after the treatment of six weeks by phytotherapy. Mean KOOS score (n=153) at the 
baseline and at the end of six weeks assessment (*p<0.0001) 
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Figure 7: AP views of x-ray for knee-joint and lumbar vertebrae before and after the treatment 
Table 5. Statistical analysis of anatomical features of 153 patients at post treatment 
Anatomical 
 parameter 
Gender 
Baseline End of 6-week 
Improvement on elevated level of anatomical parameters 
at the end of 6-week 
Mean (SEM) Mean (SEM) Right Leg Left Leg 
Rt. Lt. Rt. Lt. MD (95%CI) P-value MD (95%CI) P-value 
S
L
R
 
(d
eg
re
e)
 
Female (n=108) 
54.03 
(1.015) 
54.9 
(0.945) 
75.91 
(0.359) 
75.91 
(0.359) 
-21.88 
(-24.00, -19.76) 
<0.0001 
-21.01 
(-23.00, -19.02) 
<0.0001 
Male (n=45) 
50.78 
(1.513) 
51.82 
(1.511) 
74.82 
(0.626) 
74.82 
(0.626 
-24.04 
(-27.29, -20.78) 
<0.0001 
-23.00 
(-26.25, -19.75) 
<0.0001 
K
F
S
 
(d
eg
re
e)
 
Female (n=108) 
112.72 
(0.723) 
113.21 
(0.652) 
143.20 
(0.185) 
143.20 
(0.185) 
-30.48 
(-31.95, 29.00) 
<0.0001 
-29.99 
(-31.33, -28.65) 
<0.0001 
Male (n=45) 
112.60 
(0.961) 
112.02 
(1.030) 
142.76 
(0.283) 
142.76 
(0.283) 
-30.16 
(-32.15, -28.17) 
<0.0001 
-30.74 
(-32.86, -28.62) 
<0.0001 
K
E
S
 
(d
eg
re
e)
 
Female (n=108) 
17.50 
(0.215) 
17.39 
(0.182) 
8.76 
(0.050) 
8.76 
(0.050) 
8.70 
(8.30, 9.17) 
<0.0001 
8.63 
(8.26, 9.00) 
<0.0001 
Male (n=45) 
17.56 
(0.280) 
17.76 
(0.186) 
9.66 
(0.133) 
9.66 
(0.133) 
7.90 
(7.28, 8.52) 
<0.0001 
8.10 
(7.64, 8.55) 
<0.0001 
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Anatomical parameters: Table 5 shows that the mean 
±SEM values of SLR and KFS at post-treatment all 
increased and that decreased for KES and observed to be all 
symmetrical for both the legs. All the differences were 
highly significant (p<0.0001) when compared to pre-
treatment for both overall and separately by gender. 
The overall measurements of KGB, DAP and DBP all 
reduced  and  DCM and DTM were all increased and 
observed  to  be symmetrical for both the legs at the end of 
the 6-week treatment and were also highly significant 
(p<0.0001) when compared to the baseline [data not shown].  
Improvement on muscular strength during MD-OAD as 
per radiological image assessed by K-L grading scale: All 
the anterior-posterior (AP) views of the x-ray reports of 153 
patients with OAD at the baseline exhibited degenerative 
changes, particularly in the medial tibio-femoral 
compartment, with marked joint space narrowing and  
bilateral varus/valgus deformities. Some cases exhibited 
near-complete medial compartment joint space obliteration 
and also degenerative changes with osteophytes in the 
lumbar vertebrae. The AP view of x-ray for bilateral knee 
joints and lumbar vertebrae of patients after six-week 
treatment indicated no such degenerative changes and 
assessment under K-L grading scale shown in table-6. x-ray 
images of two such patients suffering from pain in the knee 
joint and lumbar region before and after the treatment are 
depicted in figure 7. 
 
 
Discussion  
The present results indicated that MD-OADs can easily 
be recognized by elevated biomarkers such as CK-MM and 
aldoA and their ratio. Major research works have been 
reported that elevation of two biochemical markers such as 
CK-MM and aldoA are important to detect the muscular 
dystrophy and skeletal muscle damage (17-20, 22, 27-28, 36-
38). There is currently no way to prevent or reverse MD-
OAD  but frequently different medications are used for 
temporary relief such as NSAIDs to prevent pain and 
inflammation but have tremendous side-effects like 
cardiovascular and gastrointestinal problems and 
corticosteroids, which may help to increase muscle strength 
and slow progression but can weaken bones and increase 
weight gain for long-term use and use of other kinds of 
therapies as mentioned earlier, which may improve the delay 
of progression of symptoms, thus, the quality of life may be 
saved temporarily. In the present study, males were observed 
more susceptibly than females on biomarker evaluation but 
earlier study revealed that women are more vulnerable than 
men (9, 11, 13).  
Simultaneously, the declining level of these two 
biomarkers along with improved deranged anatomical 
features, pain parameter under VAS, improvement of 
physical functional abilities and quality of life under 
WOMAC index, KPS scale, KOOS and lowering obesity 
under BMI by topical phytotherapeutic treatment protocol 
for a period of 6 weeks, was an endeavour in the present 
study. Generally, phytomedicines from medicinal plants 
derived compounds are well-established for the prevention 
of arthritis, obesity, oxidative stress, inflammation, neuro-
degenerative diseases, etc. (36-38, 49, 53-55) It was 
observed in the present study that both the biomarkers 
decreased after topical application of aqueous extract of 
medicinal plants as per research protocol developed by 
Ganguly et al. (36-37) and Ganguly (38), followed by 
Belcaro et al. (39). Both the levels of the biomarkers and 
their ratios were substantially reduced at the end of the six-
week treatment in the case of percentage improvement study 
done separately for combined-sex, female-only and male-
only patients (Table 3 and Figure 1). The author had already 
proven the efficacy of the topical phytotherapeutic treatment 
protocol by exhibiting 42 pairs of knee-joints of 21 patients 
before and after the treatment irrespective of age and sex and 
even after failed total knee surgery where all the patients 
were suffering from MD confirmed with their serum test of 
CK-MM and aldo A  (36-38, 49, 53-55) . 
The percentage improvement for the study of pain and 
related parameters were substantially achieved under the 
well-known guidelines for the standard clinical outcomes 
such as VAS, WOMAC Index, KPS, and KOOS and there is 
a reduction of body weight as assessed by BMI at the end of 
the six-week phytotherapy treatment for all the studied 
subjects. The result from the deranged anatomical 
parameters shows that there are substantially increasing and 
decreasing phenomenon of the group of muscles connected 
with various joints and both legs were symmetrical in respect 
of the measurements of KGB, DAP, DBP, DCM, DTM, 
SLR, KFS and KES at six weeks post-treatment which 
indicate the improvement of muscle wasting, muscle 
weakness and degeneration that occurred during MD-OAD 
at the baseline. Several researchers have emphasized the 
normalization of the above-mentioned parameters along with 
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the prevention of osteoarthritis in human (36-39) but the 
present study indicates aqueous extracts of medicinal plants 
and their phytoconstituents may participate individually 
and/or combination repair MD in relation to the 
normalization of biochemical markers. The correlation 
coefficient interactions highly improved after the treatment 
when compared to baseline data. It is well-known that the 
increased levels of CK-MM and aldo A in the blood of 
human indicate muscle wasting and skeletal muscle damage 
occurred in the tissue (22, 51-52, 54) in which abnormal 
muscle anatomy, pain and degenerative changes in bones 
were found (54). The present study revealed  that the 
normalization of MD-OAD of patients  is possible with the 
help of specialized  phytotherapeutic treatment protocol by  
the  evidence of declining levels  of CK-MM (for female 
<145 U/L and for male <171) and aldoA (<7.6 U/L) 
followed by the normalization of anatomical parameters 
along with the repair of OADs identified in biomarkers,  
recovery of  pain, muscle stiffness, and normal physical  day 
to day functional activities and reduction of body weight as 
assessed by the standard international clinical outcomes such 
as  VAS, WOMAC index, KPS, KOOS  and BMI together 
with the confirmed improvement  in radiological images  of 
joints.  
Moreover, the few research works have been emphasized 
on structural and functional abnormalities of dystrophin 
protein located within sarcolemma and causative factor of 
MD (12) but the exact mechanisms of MD-OADs are not 
clearly understood and researcher investigated only muscle 
damage during knee osteoarthritis (13). In conclusion, It is 
firmly concluded from the results that for the first time, 
normalization of  MD-OAD patients with  a unique method 
of topical phytotherapeutic treatment technique for 6 weeks 
is confirmed by  assessing  the decreased levels  of CK-MM 
and aldoA  along with improved deranged anatomical 
features, diminished levels of pain, stiffness, increased the 
quality of life and decreased body weight as assessed by 
VAS, WOMAC Index,  KPS, KOOS and BMI together with  
improved radiological images correlated with K-L grading 
scale. Future research should be carried out to detect the 
structural and functional abnormalities of dystrophin protein 
in serum during MD-OADs. 
Limitation of the study:  The patients suffering from 
chronic disorders are restricted to this present study such as 
Duchenne muscular dystrophy (DMD); Becker muscular 
dystrophy (BMD); rheumatic diseases; osteochondritis 
diseases;  congenital dysplasia; radicular syndrome; joint 
symptoms caused by malignant tumors; dermatomyositis and 
polymyositis diseases; iliopectineal or trochanteric bursitis; 
ischemic bone necrosis; bone and joint infectious diseases; 
cuts, wounds or any type of chronic skin and infectious 
diseases; parallel multiple drug dependence for concomitant 
diseases or risk conditions requiring drug treatment 
including psychiatric diseases; a history of cancer, including 
caranomatosis and granulocytic leukemia; a history of severe 
neurological diseases; a history of chronic liver, kidney and 
heart diseases and also patients who did not agree to give 
blood sample, may be due to drugs/alcohol addiction, 
pregnancy and such other reasons. 
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